Drug Trial Radar · NCT05067283
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
830
Planned (sponsor's estimate)
Start
Dec 17, 2021
Primary completion
Feb 25, 2030
Study completion Feb 25, 2030
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Oct 5, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study evaluating the safety, pharmacokinetics, and efficacy of calderasib alone, and calderasib plus other combination therapies in participants with advanced solid tumors with identified kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation.
Conditions
- Advanced Solid Tumors
Interventions
CalderasibDrug
Oral dose
PembrolizumabBiological
Intravenous infusion of 200 mg
carboplatinDrug
Per label
pemetrexedDrug
Per label
cetuximabBiological
Per label
oxaliplatinDrug
Per label
leucovorinDrug
Per label
5-fluorouracilDrug
Per label
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experience a Dose-Limiting Toxicity (DLT)Time frame: Up to ~21 days
- Number of Participants Who Experience an Adverse Event (AE)Time frame: Up to ~56 months
- Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to ~56 months
Locations
75 sites in 21 countries. Site status is shown where the registry gives one.
Moffitt Cancer Center ( Site 0261)
Tampa, Florida · Recruiting
START Midwest ( Site 0267)
Grand Rapids, Michigan · Recruiting
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0260)
Hackensack, New Jersey · Recruiting
Laura and Isaac Perlmutter Cancer Center ( Site 0270)
New York, New York · Completed
NEXT Virginia ( Site 0271)
Fairfax, Virginia · Recruiting
MEDICAL COLLEGE OF WISCONSIN-Cancer Center Clinical Trials Office ( Site 0262)
Milwaukee, Wisconsin · Recruiting
Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0438)
La Rioja, Argentina · Recruiting
Instituto Alexander Fleming ( Site 0434)
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina · Recruiting
Sanatorio Parque ( Site 0456)
Rosario, Santa Fe Province, Argentina · Recruiting
Chris O'Brien Lifehouse ( Site 0002)
Camperdown, New South Wales, Australia · Recruiting
Liverpool Hospital-Medical Oncology ( Site 0001)
Liverpool, New South Wales, Australia · Recruiting
Westmead Hospital ( Site 0006)
Westmead, New South Wales, Australia · Recruiting
Monash Health-Oncology Research ( Site 0003)
Clayton, Victoria, Australia · Recruiting
Cross Cancer Institute ( Site 0033)
Edmonton, Alberta, Canada · Recruiting
The Moncton Hospital ( Site 0037)
Moncton, New Brunswick, Canada · Recruiting
Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0030)
Hamilton, Ontario, Canada · Recruiting
Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 0036)
Kingston, Ontario, Canada · Recruiting
Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0032)
Toronto, Ontario, Canada · Recruiting
James Lind Centro de Investigacion del Cancer ( Site 0043)
Temuco, Araucania, Chile · Completed
Centro de Estudios Clínicos SAGA-CECSAGA ( Site 0041)
Santiago, Region M. de Santiago, Chile · Recruiting
FALP-UIDO ( Site 0040)
Santiago, Region M. de Santiago, Chile · Recruiting
Bradfordhill ( Site 0042)
Santiago, Region M. de Santiago, Chile · Recruiting
Beijing Friendship Hospital Affiliate of Capital University-Oncology ( Site 0417)
Beijing, Beijing Municipality, China · Recruiting
Fujian Cancer Hospital ( Site 0419)
Fuzhou, Fujian, China · Recruiting
Southern Medical University Nanfang Hospital-Depatrment of Respiratory and Critical Care Medicine ( Site 0413)
Guangzhou, Guangdong, China · Recruiting
Sun Yat-sen University Cancer Center-Internal medicine ( Site 0415)
Guangzhou, Guangdong, China · Recruiting
Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 0418)
Wuhan, Hubei, China · Recruiting
Jilin Cancer Hospital-oncology department ( Site 0412)
Changchun, Jilin, China · Completed
Shanghai Chest Hospital-Oncology department ( Site 0410)
Shanghai, Shanghai Municipality, China · Recruiting
Shanghai East Hospital ( Site 0416)
Shanghai, Shanghai Municipality, China · Recruiting
Zhejiang Cancer Hospital-Thoracic oncology ( Site 0411)
Hangzhou, Zhejiang, China · Recruiting
Odense Universitetshospital-Department of oncology ( Site 0421)
Odense, Region Syddanmark, Denmark · Recruiting
Rambam Health Care Campus-Oncology ( Site 0090)
Haifa, Israel · Recruiting
Shaare Zedek Medical Center-Oncology ( Site 0092)
Jerusalem, Israel · Recruiting
Hadassah Medical Center-Oncology ( Site 0094)
Jerusalem, Israel · Recruiting
Meir Medical Center. ( Site 0091)
Kfar Saba, Israel · Recruiting
Sheba Medical Center-ONCOLOGY ( Site 0093)
Ramat Gan, Israel · Recruiting
Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 0110)
Naples, Italy · Recruiting
Humanitas ( Site 0113)
Rozzano, Lombardy, Italy · Recruiting
ospedale le scotte-U.O.C. Immunoterapia Oncologica ( Site 0111)
Siena, Tuscany, Italy · Recruiting
Showing 40 of 75 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.